Measuring the Relationship of Quality of Life and Health Status: Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors

Oct 28, 2016 by in NEUROLOGICAL IMAGING Comments Off on Measuring the Relationship of Quality of Life and Health Status: Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors

Fig. 14.1 Distribution and frequency of NETs It is clear that both patients and practitioners need a heightened awareness of the symptoms of the condition that can often masquerade as other…

read more

Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment

Oct 28, 2016 by in NEUROLOGICAL IMAGING Comments Off on Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment

Fig. 12.1 Tijeras-Raballand—overview of the mechanisms of primary and acquired resistance to antiangiogenic agents Primary resistance may be due to the fact that some tumors produce redundant pro-angiogenic factors besides VEGF…

read more

Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies

Oct 28, 2016 by in NEUROLOGICAL IMAGING Comments Off on Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies

Fig. 11.1 Representative MR imaging aspects of liver metastases of well-differentiated pancreatic neuroendocrine tumors. Lesions present with a hyperintensity on T2-weighted images (a) and hypointensity on fat-saturated T1-weighted images (b). After…

read more

Scintigraphy in Endocrine Tumors of the Gut

Oct 28, 2016 by in NEUROLOGICAL IMAGING Comments Off on Scintigraphy in Endocrine Tumors of the Gut

Fig. 1.1 Patient with well-differentiated neuroendocrine tumors: Octreoscan® SPECT-CT showed liver metastases Despite greater sensitivity, limitations of Octreoscan® scintigraphy should be noted. The methodology clearly influenced the sensitivity of the examination….

read more

Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors

Oct 28, 2016 by in NEUROLOGICAL IMAGING Comments Off on Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors

Fig. 4.1 Schematic representation of the main molecular mechanisms involved in the antisecretory effects of somatostatin analogs. cAMP cyclic adenosine monophosphate; Gi G inhibitory protein; SST somatostatin; PKA protein kinase A…

read more
Premium Wordpress Themes by UFO Themes